Multiple Myeloma

Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. These cells are part of your immune system, which helps protect the body from germs and other harmful substances. In time, myeloma cells collect in the bone marrow and in the solid parts of bone.

What is Multiple Myeloma?

Multiple myeloma is a form of cancer that affects the bone marrow. The cancer is also called Kahler’s disease, named after an Austrian pathologist called Otto Kahler who first described the condition.

Multiple Myeloma Diagnosis

Multiple Myeloma Pathophysiology

Multiple Myeloma Treatment

Multiple Myeloma Epidemiology

Multiple Myeloma Symptoms

Management of Myeloma

Multiple Myeloma Imaging Strategies

Latest Multiple Myeloma News and Research

Study uncovers how cancer builds molecular bridges to evade the immune system

"Build your enemy a golden bridge to retreat across" is a piece of advice offered by Sun Tzu in his ancient military treatise, The Art of War.

23 Dec 2024

Scientists create blood test to enhance cancer treatment effectiveness

Scientists from RMIT University and the Doherty Institute have developed a new blood test that could screen cancer patients to help make their treatment safer and more effective.

16 Dec 2024

A new era of targeted therapy with antibody–drug conjugates

TBC

From Sino Biological Inc. 16 Dec 2024

Daratumumab treatment shows promise for high-risk smoldering multiple myeloma in phase 3 trial

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM).

10 Dec 2024

Interactive atlas unveils immune changes in multiple myeloma

Multiple Myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health issues.

14 Nov 2024

Stand Up To Cancer partners with Johnson & Johnson to explore new treatment for AL amyloidosis

Stand Up To Cancer (SU2C) today announced a collaboration with Johnson & Johnson aimed at supporting research testing a combination of two types of targeted therapies, teclistamab and daratumumab, to treat a rare disease called AL amyloidosis.

12 Nov 2024

VANCE trial marks milestone in t cell therapy for solid tumors

The largest ever clinical trial of T cell therapy for solid tumors has ended, heralding a new era for precision T cell therapy.

11 Nov 2024

MD Anderson launches new institute for advancing cell therapy

The University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Cell Therapy Discovery & Innovation, which will build upon longstanding MD Anderson clinical and research expertise to lead the world in developing and advancing impactful cell therapies for patients in need.

8 Nov 2024

UCLA and Parker Institute renew alliance to advance cancer immunotherapy

UCLA and the Parker Institute for Cancer Immunotherapy (PICI) have renewed their alliance to advance research in cancer immunotherapy and accelerate the development of curative treatments for the most difficult-to-treat cancers.

16 Oct 2024

Clonal competition assays reveal tumor cell resistance mechanisms

All cells within the same cancer are not the same. They all have genetic errors that turn them into tumor cells, but these errors are not identical.

8 Oct 2024

Epigenetic testing opens new doors for multiple myeloma treatment

Multiple myeloma is a type of blood cancer that appears mainly after the age of sixty. Its incidence, therefore, increases with the aging of the population.

7 Oct 2024

Excess body weight at first cancer diagnosis increases risk of second cancer

Adults with excess body weight at their first cancer diagnosis face a higher risk of developing a second primary cancer, particularly those related to obesity, according to a recent study. The research emphasizes the need for survivorship guidelines targeting weight management.

22 Sep 2024

Multiple myeloma drug shows efficacy in treating rare bleeding disorder

A drug approved for treating the blood cancer multiple myeloma may offer a safe and effective way to reduce the risk of severe nosebleeds from a rare but devastating bleeding disorder.

19 Sep 2024

Cancer drug shows promise for treating rare bleeding disorder

A clinical trial has demonstrated that the cancer drug pomalidomide is safe and effective in treating hereditary hemorrhagic telangiectasia (HHT), a rare bleeding disorder that impacts more than 1 in 5,000 people worldwide. The trial, led by Keith McCrae, M.D., of Cleveland Clinic and supported by the National Institutes of Health, was stopped early because of these successful findings, and has been published in the New England Journal of Medicine.

19 Sep 2024

Cancer patients face increased risk of long-term mental health problems

People diagnosed with cancer are at a greater risk of mental health problems even five years after their diagnosis, according to a large-scale study of data from UK GP patient records.

17 Sep 2024

New discovery offers hope for overcoming CAR-T cell therapy resistance

Mayo Clinic researchers mined the molecular foundations of cancer and uncovered a new reason chimeric antigen receptor (CAR-T cell therapy) fails in some patients.

12 Sep 2024

Study shows CAR T-cell therapy's risk of second primary malignancies comparable to other treatments

The frequency of second primary malignancies (SPMs) arising in cancer survivors following treatment with CAR T-cell therapy was statistically comparable to the frequency of SPMs following other standard-of-care therapies, according to a systematic review and meta-analysis.

11 Sep 2024

Cancer drug offers life-changing results for severe lupus patient

The team at Charité – Universitätsmedizin Berlin is astounded by the huge improvement seen in a female patient with severe systemic lupus erythematosus (SLE) after being treated with the cancer medication teclistamab. Not long ago, the 23-year-old was wheelchair-bound due to the autoimmune disease.

6 Sep 2024

New test detects cancer risk in type 2 diabetes patients

Individuals with type 2 diabetes who are at higher risk of certain cancers could be identified by a simple blood test, this year's Annual Meeting of the European Association for the Study of Diabetes (EASD) (Madrid, 9-13 September) will hear.

28 Aug 2024

Exploring targeted therapies in the complex landscape of multiple myeloma

Multiple myeloma (MM) is a complex hematological malignancy with significant unmet needs. While conventional therapies have significantly improved patient survival, the disease remains incurable.

20 Aug 2024